[1]Zheng R S, Zhang S W, Zeng H M, et al. Cancer incidence and mortality in China, 2016[J]. J Nat Cancer Cent, 2022, 2(1): 1-9.
[2]Van Roermund J G H, Bol G H, Witjes J A, et al. Periprostatic fat measured on computed tomography as a marker for prostate cancer aggressiveness[J]. World J Urol, 2010, 28(6): 699-704.
[3]Tan W P, Lin C, Chen M R, et al. Periprostatic fat: a risk factor for prostate cancer?[J]. Urology, 2016, 98: 107-112.
[4]Dahran N, Szewczyk-Bieda M, Wei C, et al. Normalized periprostatic fat MRI measurements can predict prostate cancer aggressiveness in men undergoing radical prostatectomy for clinically localised disease[J]. Sci Rep, 2017, 7(1): 4630.
[5]lvarez-Artime A, García-Soler B, Sainz R M, et al. Emerging roles for browning of white adipose tissue in prostate cancer malignant behaviour[J]. Int J Mol Sci, 2021, 22(11): 5560.
[6]Finley D S, Calvert V S, Inokuchi J, et al. Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness[J]. J Urol, 2009, 182(4): 1621-1627.
[7]Biondetti P R, Lee J K, Ling D, et al. Clinical stage B prostate carcinoma: staging with MR imaging[J]. Radiology, 1987, 162(2): 325-329.
[8]Yuh B, Wu H Q, Ruel N, et al. Analysis of regional lymph nodes in periprostatic fat following robot-assisted radical prostatectomy[J]. BJU Int, 2012, 109(4): 603-607.
[9]van Roermund J G H, Hinnen K A, Tolman C J, et al. Periprostatic fat correlates with tumour aggressiveness in prostate cancer patients[J]. BJU Int, 2011, 107(11): 1775-1779.
[10]Bhindi B, Trottier G, Elharram M, et al. Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer[J]. BJU Int, 2012, 110(7): 980-986.
[11]Woo S, Cho J Y, Kim S Y, et al. Periprostatic fat thickness on MRI: correlation with Gleason score in prostate cancer[J]. AJR Am J Roentgenol, 2015, 204(1): W43-W47.
[12]Xiong T Y, Cao F, Zhu G Y, et al. MRI-measured adipose features as predictive factors for detection of prostate cancer in males undergoing systematic prostate biopsy: a retrospective study based on a Chinese population[J]. Adipocyte, 2022, 11(1): 653-664.
[13]Zhai L Y, Fan Y, Sun S S, et al. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer[J]. Scand J Urol, 2018, 52(5/6): 333-339.
[14]Iemura Y, Hori S, Tatsumi Y, et al. Periprostatic fat thickness quantified by preoperative magnetic resonance imaging is an independent risk factor forupstaging from cT1/2 to pT3 in robot-assisted radical prostatectomy[J]. Int J Urol, 2020, 27(12): 1144-1149.
[15]Salji M, Hendry J, Patel A, et al. Peri-prostatic fat volume measurement as a predictive tool for castration resistance in advanced prostate cancer[J]. Eur Urol Focus, 2018, 4(6): 858-866.
[16]Huang H C, Chen S, Li W, et al. Periprostatic fat thickness on MRI is an independent predictor of time to castration-resistant prostate cancer in Chinese patients with newly diagnosed prostate cancer treated with androgen deprivation therapy[J]. Clin Genitourin Cancer, 2019, 17(5): e1036-e1047.
[17]Sasaki T, Sugino Y, Kato M, et al. Pre-treatment ratio of periprostatic to subcutaneous fat thickness on MRI is an independent survival predictor in hormone-nave men with advanced prostate cancer[J]. Int J Clin Oncol, 2020, 25(2): 370-376.
[18]Gregg J R, Surasi D S, Childs A, et al. The association of periprostatic fat and grade group progression in men with localized prostate cancer on active surveillance[J]. J Urol, 2021, 205(1): 122-128.
[19]Di Bella C M, Howard L E, Oyekunle T, et al. Abdominal and pelvic adipose tissue distribution and risk of prostate cancer recurrence after radiation therapy[J]. Prostate, 2020, 80(14): 1244-1252.
[20]Lee J W, Jeon Y S, Kim K H, et al. Prognostic value of CT-attenuation and 18F-fluorodeoxyglucose uptake of periprostatic adipose tissue in patients with prostate cancer[J]. J Pers Med, 2020, 10(4): 185.
[21]Tafuri A, Panunzio A, Greco F, et al. MRI-derived apparent diffusion coefficient of peri-prostatic adipose tissue is a potential determinant of prostate cancer aggressiveness in preoperative setting: a preliminary report[J]. Int J Environ Res Public Health, 2022, 19(23): 15996.
[22]Allott E H, Howard L E, Song H J, et al. Racial differences in adipose tissue distribution and risk of aggressive prostate cancer among men undergoing radiotherapy[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23(11): 2404-2412.
[23]Taussky D, Barkati M, Campeau S, et al. Changes in periprostatic adipose tissue induced by 5α-reductase inhibitors[J]. Andrology, 2017, 5(3): 511-515.
[24]Venkatasubramanian P N, Brendler C B, Plunkett B A, et al. Periprostatic adipose tissue from obese prostate cancer patients promotes tumor and endothelial cell proliferation: a functional and MR imaging pilot study[J]. Prostate, 2014, 74(3): 326-335.
[25]Iordanescu G, Brendler C, Crawford S E, et al. MRS measured fatty acid composition of periprostatic adipose tissue correlates with pathological measures of prostate cancer aggressiveness[J]. J Magn Reson Imaging, 2015, 42(3): 651-657.
[26]Miladinovic D, Cusick T, Mahon K L, et al. Assessment of periprostatic and subcutaneous adipose tissue lipolysis and adipocyte size from men with localized prostate cancer[J]. Cancers (Basel), 2020, 12(6): 1385.
[27]Roumiguié M, Estève D, Manceau C, et al. Periprostatic adipose tissue displays a chronic hypoxic state that limits its expandability[J]. Am J Pathol, 2022, 192(6): 926-942.
[28]Fontaine A, Bellanger D, Guibon R, et al. Lipophagy and prostate cancer: association with disease aggressiveness and proximity to periprostatic adipose tissue[J]. J Pathol, 2021, 255(2): 166-176.
[29]Altuna-Coy A, Ruiz-Plazas X, Sánchez-Martin S, et al. The lipidomic profile of the tumoral periprostatic adipose tissue reveals alterations in tumor cells metabolic crosstalk[J]. BMC Med, 2022, 20(1): 255.
[30]Ribeiro R, Monteiro C, Catalán V, et al. Obesity and prostate cancer: gene expression signature of human periprostatic adipose tissue[J]. BMC Med, 2012, 10: 108.
[31]Mangiola S, Stuchbery R, Macintyre G, et al. Periprostatic fat tissue transcriptome reveals a signature diagnostic for high-risk prostate cancer[J]. Endocr Relat Cancer, 2018, 25(5): 569-581.
[32]Cheng Y, Monteiro C, Matos A, et al. Epigenome-wide DNA methylation profiling of periprostatic adipose tissue in prostate cancer patients with excess adiposity-a pilot study[J]. Clin Epigenetics, 2018, 10: 54.
[33]Zhang Q,Sun L J, Qi J, et al. Influence of adipocytokines and periprostatic adiposity measurement parameters on prostate cancer aggressiveness[J]. Asian Pac J Cancer Prev, 2014, 15(4): 1879-1883.
[34]Zhang Q, Sun L J, Yang Z G, et al. Influence of adipocytokines in periprostatic adipose tissue on prostate cancer aggressiveness[J]. Cytokine, 2016, 85: 148-156.
[35]Dahran N, Szewczyk-Bieda M, Vinnicombe S, et al. Periprostatic fat adipokine expression is correlated with prostate cancer aggressiveness in men undergoing radical prostatectomy for clinically localized disease[J]. BJU Int, 2019, 123(6): 985-994.
[36]Gucalp A, Iyengar N M, Zhou X K, et al. Periprostatic adipose inflammation is associated with high-grade prostate cancer[J]. Prostate Cancer Prostatic Dis, 2017, 20(4): 418-423.
[37]Miyazawa M, Subbaramaiah K, Bhardwaj P, et al. Pioglitazone inhibits periprostatic white adipose tissue inflammation in obese mice[J]. Cancer Prev Res (Phila), 2018, 11(4): 215-226.
[38]Bhardwaj P, Ikeda T, Zhou X K, et al. Supplemental estrogen and caloric restriction reduce obesity-induced periprostatic white adipose inflammation in mice[J]. Carcinogenesis, 2019, 40(7): 914-923.
[39]Mangiola S, Stuchbery R, McCoy P, et al. Androgen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat[J]. Endocr Connect, 2019, 8(5): 547-558.
[40]Ribeiro R, Monteiro C, Cunha V, et al. Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro[J]. J Exp Clin Cancer Res, 2012, 31(1): 32.
[41]La Civita E, Liotti A, Cennamo M, et al. Peri-prostatic adipocyte-released TGFβ enhances prostate cancer cell motility by upregulation of connective tissue growth factor[J]. Biomedicines, 2021, 9(11): 1692.
[42]Figiel S, Bery F, Chantme A, et al. A novel calcium-mediated EMT pathway controlled by lipids: an opportunity for prostate cancer adjuvant therapy[J]. Cancers (Basel), 2019, 11(11): 1814.
[43]Laurent V, Toulet A, Attané C, et al. Periprostatic adipose tissue favors prostate cancer cell invasion in an obesity-dependent manner: role of oxidative stress[J]. Mol Cancer Res, 2019, 17(3): 821-835.
[44]Laurent V, Guérard A, Mazerolles C, et al. Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity[J]. Nat Commun, 2016, 7: 10230.
[45]Xu L J, Shen M J, Chen X D, et al. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells[J]. Prostate, 2018, 78(5): 353-364.
[46]Liotti A, La Civita E, Cennamo M, et al. Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF-1 upregulation of TUBB2B beta-tubulin isoform[J]. Prostate, 2021, 81(7): 407-417.
[47]Lin G, Yang R, Banie L, et al. Effects of transplantation of adipose tissue-derived stem cells on prostate tumor[J]. Prostate, 2010, 70(10): 1066-1073.
[48]Feng S Z, Lou K C, Luo C, et al. Obesity-related cross-talk between prostate cancer and peripheral fat: potential role of exosomes[J]. Cancers (Basel), 2022, 14(20): 5077.
[49]Sacca P A, Mazza O N, Scorticati C, et al. Human periprostatic adipose tissue: secretome from patients with prostate cancer or benign prostate hyperplasia[J]. Cancer Genomics Proteomics, 2019, 16(1): 29-58.
|